-
Digestion 1982The semen of 11 patients with inflammatory bowel disease treated with sulphasalazine (Salazopyrin) was analysed and compared with that of 6 men with similar disease not...
The semen of 11 patients with inflammatory bowel disease treated with sulphasalazine (Salazopyrin) was analysed and compared with that of 6 men with similar disease not treated with the drug. The treated group had significantly reduced sperm population density and motility compared with the untreated group. Both groups had high numbers of abnormal spermatozoa compared with the standard for our laboratory, but there was no significant difference between the two groups for this parameter. Sulphasalazine has a deleterious effect on spermatogenesis.
Topics: Adolescent; Adult; Colitis, Ulcerative; Crohn Disease; Humans; Male; Middle Aged; Spermatogenesis; Sulfasalazine
PubMed: 6123457
DOI: 10.1159/000198712 -
The Journal of Rheumatology Feb 1989
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine
PubMed: 2568487
DOI: No ID Found -
Drugs 1986Studies of sulphasalazine in rheumatoid arthritis have used largely empirical doses. The available literature suggests that the optimum dose appears to be greater than... (Review)
Review
Studies of sulphasalazine in rheumatoid arthritis have used largely empirical doses. The available literature suggests that the optimum dose appears to be greater than 40 mg/kg/day. Despite the relationship between dose and efficacy and a good correlation between dose and serum concentrations of sulphasalazine and its metabolites, no relationship has been demonstrated between efficacy and serum concentrations of sulphasalazine or its metabolites, although there is some suggestion that higher concentrations on single dosing are achieved in patients who develop upper gastrointestinal symptoms. Furthermore, acetylator phenotype does not affect efficacy, although upper gastrointestinal symptoms are more common in slow acetylators.
Topics: Acetylation; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Humans; Sulfasalazine
PubMed: 2877854
DOI: 10.2165/00003495-198600321-00011 -
British Journal of Rheumatology Nov 1995Sulphasalazine is cleaved into 5-aminosalicylic acid and sulphapyridine by colonic bacteria. The bulk of evidence favours sulphapyridine rather than 5-aminosalicylic... (Review)
Review
Sulphasalazine is cleaved into 5-aminosalicylic acid and sulphapyridine by colonic bacteria. The bulk of evidence favours sulphapyridine rather than 5-aminosalicylic acid as the active moiety (as well as the main producer of side-effects) though a therapeutic action from the 30% of sulphasalazine that is absorbed unaltered also cannot be excluded.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Humans; Mesalamine; Sulfapyridine; Sulfasalazine
PubMed: 8535642
DOI: No ID Found -
British Medical Journal (Clinical... Sep 1983
Topics: Child; Colitis, Ulcerative; Dysgammaglobulinemia; Humans; IgA Deficiency; Male; Sulfasalazine
PubMed: 6137259
DOI: 10.1136/bmj.287.6394.759 -
Postgraduate Medicine Dec 1983Published studies suggest that sulfasalazine is effective in treating mild to moderate attacks of ulcerative colitis. Its usefulness in severe attacks has not been...
Published studies suggest that sulfasalazine is effective in treating mild to moderate attacks of ulcerative colitis. Its usefulness in severe attacks has not been adequately tested. Published reports also justify the use of sulfasalazine to prevent recurrence of ulcerative colitis. It is not clear how long maintenance therapy should be continued, but evidence to date favors prolonged treatment in the absence of side effects. In treatment of Crohn's disease, sulfasalazine has been shown to be effective when disease involves the colon or the colon and small intestine. Maintenance therapy does not prevent relapse. Recent studies have indicated that 5-aminosalicylic acid (5-ASA) may be the therapeutic moiety of sulfasalazine, and sulfapyridine (SP) may be related to most of the side effects. Therefore, research is under way to develop a product that contains 5-ASA without the sulfonamide component and that is capable of reaching the colon without being absorbed in the upper small intestine.
Topics: Aminosalicylic Acids; Bacteria; Colitis, Ulcerative; Colon; Crohn Disease; Humans; Kinetics; Mesalamine; Prostaglandins; Sulfapyridine; Sulfasalazine
PubMed: 6139795
DOI: 10.1080/00325481.1983.11698537 -
Drug and Therapeutics Bulletin Nov 1967
-
Thorax Nov 1972Sulphasalazine is a drug which is widely used in the treatment of ulcerative colitis. Although a high incidence of side effects has been reported, pulmonary...
Sulphasalazine is a drug which is widely used in the treatment of ulcerative colitis. Although a high incidence of side effects has been reported, pulmonary complications of treatment have not been described previously. The clinical, haematological, and radiological abnormalities which occurred in one patient two months after sulphasalazine was started are described. Withdrawal of treatment was followed by recovery; reintroduction of the drug caused a relapse associated with eosinophilia and impaired pulmonary function. We suggest that the possibility of drug-induced lung disease should be considered in any patient who develops symptoms or radiographic evidence of pulmonary disease while receiving treatment with sulphasalazine.
Topics: Adult; Colitis, Ulcerative; Eosinophilia; Female; Humans; Lung Diseases; Physical Exertion; Radiography; Recurrence; Spirometry; Sulfasalazine; Vital Capacity
PubMed: 4405270
DOI: 10.1136/thx.27.6.713 -
Lancet (London, England) May 1985
Topics: Arthritis, Rheumatoid; Humans; Sulfasalazine
PubMed: 2860375
DOI: 10.1016/s0140-6736(85)92477-8 -
British Medical Journal Feb 1980Seventy-four patients with rheumatoid arthritis were treated with sulphasalazine. There was a significant improvement in clinical score, with substantial falls in serum...
Seventy-four patients with rheumatoid arthritis were treated with sulphasalazine. There was a significant improvement in clinical score, with substantial falls in serum C-reactive protein concentrations and erythrocyte sedimentation rate four weeks after starting the drug. Improvement was maintained in the 38 patients who remained on the drug for one year. The mean Rose-Waaler titre did not change. There was little difference between the results in seropositive and seronegative patients. The commonest adverse effect was dyspepsia, but five patients developed a megaloblastic anaemia and one patient neutropenia; all made a complete recovery. The results suggest that the drug has a disease-modifying action not attributable to its "salicylate" content. The mode of action might be by an antibacterial effect on gut flora.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Humans; Male; Middle Aged; Sulfasalazine
PubMed: 6102877
DOI: 10.1136/bmj.280.6212.442